Lack of association between the CALM1 core promoter polymorphism (-16C/T) and susceptibility to knee osteoarthritis in a Chinese Han population

Dongquan Shi†1,2, Haijian Ni†1, Jin Dai1,2, Jianghui Qin1, Yong Xu1, Lunqing Zhu1, Chen Yao1, Zhenxing Shao1, Dongyang Chen1, Zhihong Xu1, Long Yi3, Shiro Ikegawa4 and Qing Jiang*1,2

Address: 1The Center of Diagnosis and Treatment for Joint Disease, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing 210008, Jiangsu, PR China, 2Laboratory for Bone and Joint Diseases, Model Animal Research Center, Nanjing University, Nanjing 210061, Jiangsu, PR China, 3Department of Pathology, Medical School of Nanjing University, PR China and 4Laboratory for Bone and Joint Diseases, Center for Genomic Medicine, Riken, Tokyo 108-8639, Japan

Email: Dongquan Shi - tim801215@hotmail.com; Haijian Ni - nihaijian19830127@163.com; Jin Dai - daijin_nju@163.com; Jianghui Qin - jianghui.qin@hotmail.com; Yong Xu - xuyong4849@163.com; Lunqing Zhu - zlq1214@126.com; Chen Yao - doc.yaochen@gmail.com; Zhenxing Shao - backstreetwuya@hotmail.com; Dongyang Chen - amoysun@hotmail.com; Zhihong Xu - xuzhihongjoint@hotmail.com; Long Yi - yilong@nju.edu.cn; Shiro Ikegawa - sikegawa@ims.u-tokyo.ac.jp; Qing Jiang* - qingj@nju.edu.cn

* Corresponding author   †Equal contributors

Abstract

Background: CALM1 gene encodes calmodulin (CaM), an important and ubiquitous eukaryotic Ca²⁺-binding protein. Several studies have indicated that a deficient CaM function is likely to be involved in the pathogenesis of osteoarthritis (OA). Using a convincing genome-wide association study, a Japanese group has recently demonstrated a genetic association between the CALM1 core promoter polymorphism (-16C/T transition SNP, rs12885713) and OA susceptibility. However, the subsequent association studies failed to provide consistent results in OA patients of differently selected populations. The present study is to evaluate the association of the -16C/T polymorphism with knee OA in a Chinese Han population.

Methods: A case-control association study was conducted. The polymorphism was genotyped in 183 patients who had primary symptomatic knee OA with radiographic confirmation and in 210 matched controls. Allelic and genotypic frequencies were compared between patients and control subjects.

Results: No significant difference was detected in genotype or allele distribution between knee OA and control groups (all P > 0.05). The association was also negative even after stratification by sex. Furthermore, no association between the -16C/T SNP genotype and the clinical variables age, sex, BMI (body mass index) and K/L (Kellgren/Lawrence) score was observed in OA patients.

Conclusion: The present study suggests that the CALM1 core promoter polymorphism -16C/T is not a risk factor for knee OA susceptibility in the Chinese Han population. Further studies are needed to give a global view of this polymorphism in pathogenesis of OA.
Background

Osteoarthritis (OA) is a common musculoskeletal disease among the elderly, characterized by the degradation of articular cartilage and formation of abnormal bone (osteophyte). It is a multifactorial disorder in which aging, genetic, hormonal and mechanical factors are all major contributors to its onset and progression [1]. Results of family-based and candidate gene studies have demonstrated a clear genetic component, particularly for early-onset OA [2-4]. The identification of candidate genes for OA susceptibility has mainly focused on genes encoding collagens (particularly for type II collagen), for other structural proteins of the extracellular cartilage matrix (ECM), the vitamin D and estrogen receptor genes, and for bone and cartilage growth factors [5]. And it is expected that some genes which regulate the formation, degradation, and repair of articular cartilage and subchondral bone metabolism may determine the occurrence of osteoarthritis. However, the specific underlying genetic factors and mechanisms in the development of osteoarthritis need to be further researched.

Calmodulin 1 gene (CALM1) encodes calmodulin (CaM), a ubiquitous eukaryotic Ca\(^{2+}\)-binding protein which regulates many Ca\(^{2+}\)-dependent cellular events by interacting with a heterogeneous group of target proteins [6]. Several studies have indicated that calmodulin probably plays a crucial role in articular cartilage on at least three aspects: regulating articular chondrogenesis [7], maintaining the cartilage phenotype in response to mechanical stimuli in mature chondrocytes [8,9] and modulating adhesion of chondrocytes to extracellular matrix proteins during the cartilage repairing process [10]. Consequently, a deficiency of Ca\(^{2+}\)-calmodulin signal may be involved in the pathogenesis of OA.

Through a genome-wide association study, Mototani et al [7] previously reported a functional single nucleotide polymorphism (SNP) (-16C/T rs12885713) in the core promoter region of the CALM1 gene associated with a markedly increased prevalence of hip OA in the Japanese population. Subsequent functional analyses revealed that the susceptibility -16T allele of this polymorphism decreased CALM1 transcription both in vitro and in vivo. In addition, higher levels of CALM1 expression in hip and knee OA cartilage than in normal were also observed [7].

Together, these findings implicated the candidacy of CALM1 as a susceptibility gene for OA. However, subsequent association studies [11,12] failed to provide consistent results in OA patients of differently selected populations. To clarify its global relevance, the association needs to be confirmed by independent studies in different ethnic groups. The objective of this study is to assess the genetic association of the -16C/T polymorphism in CALM1 with knee OA in a Chinese Han population.

Methods

Subjects

A total of 183 patients with primary knee OA (124 women and 59 men) were recruited consecutively at the Center of Diagnosis and Treatment for Joint Disease, Drum Tower Hospital, affiliated to the Medical School of Nanjing University and 210 healthy control subjects (142 women and 68 men) were recruited at the Center of Physical Examination. All subjects included in the study were Han Chinese living in or around Nanjing. The study was approved by the ethics review committee of the Medical School of Nanjing University and written informed consent was obtained from all participants. The ascertainment criteria for both OA patients and control subjects were according to the previously published study by Jiang et al [13]. In the study, other etiologies causing knee diseases such as inflammatory arthritis (rheumatoid, polyarthritis, or autoimmune disease), posttraumatic or post-septic arthritis, skeletal dysplasia or developmental dysplasia were excluded. Radiographic OA was assessed using the Kellgren/Lawrence (K/L) grading system [14]. Only patients with K/L grades of 2 or higher were included. All the control never had any signs or symptoms of arthritis or joint diseases (pain, swelling, tenderness, or restriction of movement).

Genotyping

Genomic DNA was extracted from peripheral blood leukocytes using the Chelex-100 method [15] or from buccal swabs using the DNA IQ System (Promega, Madison, WI) according to the manufacturer's instructions. PCR amplifications were performed for the -16C/T SNP using forward primer 5' GCC GGA GGC CTG GCG AAC 3' and reverse primer 5' CAC TGC CGG AGC GCG AGT GT3'. The italic and boldfaced nucleotide in the reverse primer is a G as opposed to the C that exists in the CALM1 sequence in order to create a APAL1 restriction enzyme site in the T-allele of the SNP which is absent in the C-allele. The amplification solution system was supplemented with 5% dimethyl sulfoxide (DMSO) [11]. Amplification was carried out as follows: 31 cycles consisting of 1 min of denaturation at 94°C, 1 min of annealing at 62°C and 1 min of extension at 72°C with an initial denaturation step of 2 min at 96°C and a final extension of 15 min at 72°C. The 148 bp PCR product was then digested with APAL1 (New England Biolabs, Hitchin, UK). After that, a T-allele was digested into two fragments, of 125 bp and 23 bp, whilst a C-allele remained uncut. Restriction fragments were separated by 3% agarose gel electrophoresis and ethidium bromide staining. To verify the results of the original assay, randomly selected 10% samples were amplified using a second pair of sequencing primers: for-
ward 5’CTT CCC CGA CCC AGC GTA3’ and reverse 5’CGC CGC CTG ACT ACG AGT AAC3’. The 244 bp product was then digested with HpyCH4V. A T-allele was cut into two fragments, of 174 bp and 70 bp, while a C-allele, again, remained uncut. Genotyping was done by laboratory personnel blinded to case status, and a random 5% of the samples were repeated to validate genotyping procedures. Two authors independently reviewed the genotyping results, data entry, and statistical analyses.

**Statistical analysis**

For this case-control association study, we used standard χ² tests to determine the significance of differences in allelic and genotypic frequencies between OA patients and control subjects. P < 0.05 was considered statistically significant. Allele and genotype proportions were tested for Hardy-Weinberg equilibrium. Clinical variables age, sex, BMI (body mass index) and K/L score of OA patients with different genotype were compared using χ² tests or Kruskal-Wallis tests. Power estimates were calculated using the software R.

**Results**

Table 1 shows the basic characteristics of the study population. The patients and the controls were matched in age and sex. Over 59% of the patients had a K/L score of 3 or 4. Table 2 shows the allele and genotype distributions for cases and controls. Both of the allele and genotype proportions were in Hardy-Weinberg equilibrium. The recessive allele (T) and genotype (TT) frequencies of controls (20.5% and 3.8%, respectively) were similar to those previously published in the Japan population [7] (P = 0.023 and 0.064) but not to those of UK Caucasians [11] (P = 0.000 and 0.000). In the association study, no significant differences between cases and controls were observed either in allele (P = 0.996) or genotype (P = 0.802) frequencies, and the allele frequencies were even the same between the two groups. Stratifying the samples by sex did not result in any significant association (Table 2). Moreover, we did not find any association between the -16C/T SNP genotype and the clinical variables age, sex, BMI and K/L score in OA patients (Table 3 and Table 4). The power for this study was over 0.05.

**Discussion**

Through a large-scale association study with subsequent functional researches, the Japanese group have demonstrated a convincing association between the CALM1 core promoter polymorphism and Japanese hip OA. The well clarified role Ca²⁺-calmodulin signal played in chondrogenesis and normal cartilage phenotype maintaining, together with the results of the microarray analysis [7] showing higher levels of CALM1 expression both in hip and knee OA, have interested us in assessing whether this genetic polymorphism is also associated with OA in a Chinese Han population. However, we failed to find any positive result. Before the present study, this potential association had also been studied in UK Caucasian populations [11,12], yielding no positive findings either in hip or knee OA patients. Together, these studies highlight the complexity and diversity of genetic contributions to such a multifactorial disease as OA.

The “T” allele and “TT” genotype frequencies of controls in present study were very similar to those in the original study of the Japan group but different to those in the UK study [12]. The “T” allele even seemed to be the major allele in UK Caucasians instead of the allele “C” which was dominant in both the present and the Japanese studies, indicating a heterogenous nature of this polymorphism between Asians and UK Caucasians. The different ethnic background and the potential linkage disequilibrium (LD) of the -16C/T locus with some other more relevant allele or alleles within the CALM1 gene that differ in different populations, may be one of the most likely explanations for the failure to replicate the association of -16C/T with OA susceptibility in UK Caucasians.

Recently, several population-based association studies for other OA susceptibility genes have shown consistent results in the Japanese and Chinese Han populations [13,16]. Populations from neighboring regions may have greater similarities in genome for the fact that they share more recent common ancestors. Therefore, their allele frequencies are more highly correlated, a pattern that is commonly manifested as a cline of allele frequencies [17]. All these together had encouraged us to expect a positive association of -16C/T polymorphism in our population-based study, except for the fact that there is an obvious differ-

**Table 1: Subject characteristics**

| Subjects   | Number | Sex            | Age (years) | BMI | K-L score |
|------------|--------|----------------|-------------|-----|-----------|
|            |        |                | Female(%)   |     | Male      |
|            |        |                | Mean        | SD(±) | Mean | SD(±) | ≥2 | ≥ 3(%) |
| OA cases   | 183    | 124(67.8)      | 59          | 58.6 | 13.5 | 25.4 | 3.5 | 75   | 108(59) |
| Controls   | 210    | 142(67.6)      | 68          | 57.7 | 11.7 | 23.2 | 3.9 |       |         |

BMI: body mass index.
ence in clinical phenotype of OA patients between the present and the original Japanese studies - the different joint site affected, which may account for the inconsistent results of the two studies. It is becoming more apparent that the nature of OA genetic susceptibility is likely to vary between different joint sites [18]. In the RHOB and TXNDC3 studies, different associations were detected for the different affected joint sites [19-21]. A relatively small population size might have prevented from seeing the association. The proportion of genetic contribution of certain polymorphic locus to OA susceptibility may be influenced by other local environmental factors such as anatomical and biomechanical effects, and by some joint-specific genetic factors most of which were postulated to be involved in cell signalling and signal transduction [18,22]. Interestingly, CALM1 is only one member of the CALM family by which mammalian CaM is encoded. The CALM family includes three nonallelic genes CALM1, CALM2 and CALM3 located on chromosomes 14q24-q31, 2p21.1-p21.3 and 19q13.2-q13.3, respectively, but all these three genes encode an identical 148 amino acid protein CaM [23]. However, the transcriptional activity and the proportion of each gene contributing to the local mRNA pools seem to differ during cell differentiation processes or in different biochemical microenvironments [24,25]. Thus, the other two CALM genes that are more functionally active in the knee joint might have decreased the extent to which the CALM1 OA risk is manifest. To make our study more complete and comparable, it is necessary to collect enough samples of hip OA despite of the very much lower prevalence [26], and assess the association between this polymorphism and hip OA in the same Chinese population.

Moreover, Hoaglund [27] has recently made a comment on the ascertainment criteria used for the patient enrollment in the Japanese association study and has suggested that the CALM1 core promoter polymorphism may be associated with Japanese congenital hip disease causing secondary hip OA rather than primary hip OA. Colleagues in our department are now trying to identify this hypothesis by assessing the association in patients of developmental dysplasia of the hip (DDH) which may represent a severe phenotype of congenital hip disease.

**Conclusion**

The present study did not find any significant association between the CALM1 core promoter polymorphism (-16C/T) and susceptibility to knee OA in the Chinese Han population. Further studies are necessary to identify the association of this polymorphism with hip OA in our population and with OA in other different populations on different joint sites to give a global view of this polymorphism in pathogenesis of OA.

### Table 2: Association of SNP rs12885713 between OA cases and controls

| Subjects                  | Allele     | Genotype   |
|---------------------------|------------|------------|
|                           | C(%)       | T(%)       | *P value*  | CC(%)       | CT(%)       | TT(%)       | *P value*  |
| All cases (n = 183)       | 291(79.5)  | 75(20.5)   | 0.996      | 117(63.9)   | 57(31.1)    | 9(4.9)      | 0.802      |
| All controls (n = 210)    | 334(79.5)  | 86(20.5)   |            | 132(62.9)   | 70(33.3)    | 8(3.8)      |            |
| Female cases (n = 124)    | 198(79.8)  | 50(20.2)   | 0.818      | 79(63.7)    | 40(32.3)    | 5(4.0)      | 0.941      |
| Female controls (n = 142) | 229(80.6)  | 55(19.4)   |            | 93(65.5)    | 43(30.3)    | 6(4.2)      |            |
| Male cases (n = 59)       | 93(78.8)   | 25(21.2)   | 0.758      | 38(64.4)    | 17(28.8)    | 4(6.8)      | 0.313      |
| Male controls (n = 68)    | 105(77.2)  | 31(22.8)   |            | 39(57.4)    | 27(39.7)    | 2(2.9)      |            |

*Odds ratio and *P* value were calculated on recessive model (TT versus CT + CC).

### Table 3: Clinical variables in the OA patients and the rs12885713 genotype

| Variable | Genotype | CC | CT | TT | *P value* |
|----------|----------|----|----|----|-----------|
|          |          | Mean | SD | Mean | SD | Mean | SD |
| Age      |          | 57.7 | 13.0 | 59.6 | 14.7 | 64.4 | 11.3 | 0.23a  |
| BMI      |          | 25.4 | 3.1 | 25.7 | 4.2 | 24.7 | 4.1 | 0.87a  |
| Sex (Male %) |        | 32.5 | 29.8 | 44.4 | 4.4 | 0.68b |

BMI: body mass index.

a The *P* values were calculated using Kruskal-Wallis test.

b The *P* values were calculated using *χ*2 test.

### Table 4: Genotype distribution of OA subgroups stratified by K/L score

| K/L score | Total | CC(%) | CT(%) | TT(%) | *P value* |
|-----------|-------|-------|-------|-------|-----------|
| 2         | 75    | 50(66.7) | 21(28.0) | 4(5.3) | 0.86      |
| 3         | 54    | 37(68.5) | 15(27.8) | 2(3.7) |            |
| 4         | 54    | 32(59.3) | 19(35.2) | 3(5.5) |            |

* The *P* value was calculated using 3 × 3 *χ*2 test.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HN carried out the molecular genetic studies, performed the statistical analysis and drafted the manuscript. JD, IQ, YX, CY, LZ participated in sample collection and DNA extraction. LY participated in the design of the study and help to carry out the molecular genetic studies. QJ and DS conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by the National Nature Science Foundation of China (30571874), Programme of Technology Development of Nanjing (200603001) and Scientific Research Foundation for Young Doctors of Drum Tower Hospital (2007).

References
1. Arden N, Nevitt MC: Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006, 20:3-25.
2. MacGregor AJ, Antoniadis L, Matson M, Andrew T, Spector TD: The genetic contribution to radiographic hip osteoarthritis in women: results of a classic twin study. Arthritis Rheum 2000, 43:2410-2416.
3. Felson DT, Couppomitree NN, Chaisson CE, Hannan MT, Zhang Y, McAlindon TE, LaValley M, Levy D, Myers RH: Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: the Framingham Study. Arthritis Rheum 1998, 41:1064-1071.
4. Shi D, Nakamura T, Dai J, Li Y, Qin J, Chen D, Xu Z, Wang Y, Ikegawa S, Jiang Q: Association of the aspartic acid-repeat polymorphism in the asporin gene with age at onset of knee osteoarthritis in Han Chinese population. J Hum Genet 2007, 52:664-667.
5. Loughlin J: Genetic epidemiology of primary osteoarthritis. Curr Opin Rheumatol 2001, 13:111-116.
6. Berndige MJ, Bootman MD, Lipp P: Calcium—a life and death signal. Nature 1998, 395:643-648.
7. Mototani H, Mabuchi A, Saito S, Fujikoa M, Iida A, Takatori Y, Kotani A, Kubo T, Nakamura K, Sekine A, Murakami Y, Tsunoda T, Notoya K, Nakamura Y, Ikegawa S: A functional single-nucleotide polymorphism in the core promoter region of CALM1 is associated with hip osteoarthritis in Japanese. Hum Mol Genet 2005, 14:1009-1017.
8. Valmu WB, Stazzone EJ, Bachrach NM, Saed-Nejad F, Fischer SG, Mow VC, Ratcliffe A: Load-controlled compression of articular cartilage induces a transient stimulation of aggrecan gene expression. Arch Biochem Biophys 1998, 353:29-36.
9. Valmu WB, Raia FJ: Myo-Inositol 1,4,5-trisphosphate and Ca(2+)/calmodulin-dependent factors mediate transduction of compression-induced signals in bovine articular chondrocytes. Biochem J 2002, 361:689-696.
10. Piperno M, Reboul P, Helleo le Graveyard MP, Peschard M, Annfeld M, Richard M, Vignon E: Osteoarthritic cartilage fibration is associated with a decrease in chondrocyte adhesion to fibronectin. Osteoarth Cartilage 1998, 6:393-399.
11. Loughlin J, Sinchheimer JS, Carr A, Chapman K: The CALM1 core promoter polymorphism is not associated with hip osteoarthritis in a United Kingdom Caucasian population. Osteoarthri Cartilage 2006, 14:295-298.
12. Valdes AM, Loughlin J, Gene MV, Chapman K, Sorudlescus GL, Doherty M, Spector TD: Sex and ethnic differences in the association of ASPN, CALM1, COL2A1, COMP, and FRZB with genetic susceptibility to osteoarthritis of the knee. Arthritis Rheum 2007, 56:137-146.
13. Jiang Q, Shi D, Li L, Ikegawa S, Wang Y, Nakamura T, Qiao D, Liu C, Dai J: Replication of the association of the aspartic acid repeat polymorphism in the asporin gene with knee-osteoarthritis susceptibility in Han Chinese. J Hum Genet 2006, 51:1068-1072.
14. Kelgiren JH, Lawrence JS: Radiological assessment of osteoarthritis. Ann Rheum Dis 1963, 22:337-355.
15. Walsh PS, Metzger DA, Higuchi R: Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 1991, 10:506-513.
16. Miyamoto Y, Mabuchi A, Shi D, Kubo T, Takatori Y, Saito S, Fujikoa M, Sudo A, Uchida A, Yamanato S, Ozaki K, Takigawa M, Tanaka T, Nakamura Y, Jiang Q, Ikegawa S: A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet 2007, 39:529-533.
17. Basmad M, Wooding S, Salisbury BA, Stephens JC: Deconstructing the relationship between genetics and race. Nat Rev Genet 2004, 5:598-609.
18. Peach CA, Carr AJ, Loughlin J: Recent advances in the genetic investigation of osteoarthritis. Trends Med Med 2005, 11:186-191.
19. Loughlin J: Polymorphism in signal transduction is a major route through which osteoarthritis susceptibility is acting. Curr Opin Rheumatol 2005, 17:629-633.
20. Mahr S, Burmester GR, Hille D, Gobel U, Grutzka AU, Haupl T, Hauschild M, Koczlan D, Krenn V, Neidel J, Perka C, Radbruch A, Thiesen HJ, Muller B: cis- and trans-acting gene regulation is associated with osteoarthritis. Am J Hum Genet 2006, 78:793-803.
21. Loughlin J, Meulenbelt I, Min J, Mustafa Z, Sinchheimer JS, Carr A, Slagboom PE: Genetic association analysis of RHOB and TXNDC3 in osteoarthritis. Am J Hum Genet 2007, 80:383-386.
22. Shi D, Nakamura T, Nakajima M, Dai J, Qin J, Ni H, Xu Y, Yao C, Wei J, Liu B, Ikegawa S, Jiang Q: Association of single-nucleotide polymorphisms in RHOB and TXNDC3 with knee osteoarthritis susceptibility: two case-control studies in East Asian populations and a meta-analysis. Arthritis Res Ther 2008 in press.
23. Berchtold MW, Egli R, Rhyner JA, Hameister H, Strehler EE: Localization of the human bona fide calmodulin genes CALM1, CALM2, and CALM3 to chromosomes 14q24-q31, 2p21.1-q35, and 19q13.2-q13.3. Genomics 1993, 16:461-465.
24. Toutenhoofd SL, Strehler EE: Regulation of calmodulin mRNAs in differentiating human IMR-32 neuroblastoma cells. Biochim Biophys Acta 2002, 1600:95-104.
25. Toutenhoofd SL, Feletti D, Wiciki R, Rhyner JA, Garcia F, Tolon R, Strehler EE: Characterization of the human CALM2 calmodulin gene and comparison of the transcriptional activity of CALM1, CALM2 and CALM3. Cell Calcium 1998, 23:323-338.
26. Xu L, Nevitt MC, Zhang Y, Yu W, Alibadi F, Felson DT: High prevalence of knee, but not hip or hand osteoarthritis in Beijing elders: comparison with data of Caucasian in United States. Zhonghua Yi Xue Za Zhi 2003, 83:1206-1209.
27. Hoaglund FT: CALM1 promoter polymorphism gene and Japanese congenital hip disease. Osteoarthritis Cartilage 2007, 15:S93.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/9/91/prepub